Janney Montgomery Scott LLC Reduces Holdings in Kenvue Inc. $KVUE

Key Points

• Janney Montgomery Scott LLC reduced its stake in Kenvue Inc. by 7.7% during the 2nd quarter, owning 1,352,353 shares worth approximately $28.3 million after selling 113,114 shares.
• Kenvue's EPS for the last quarter was reported at $0.29, slightly beating analysts' estimates of $0.28, though its revenue was down by 4.0% year-over-year.
• The company recently announced a quarterly dividend of $0.2075, marking a slight increase from the previous dividend of $0.21, resulting in an annualized yield of 5.2%.

Janney Montgomery Scott LLC reduced its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 7.7% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 1,352,353 shares of the company's stock after selling 113,114 shares during the quarter. Janney Montgomery Scott LLC owned 0.07% of Kenvue worth $28,305,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Pittenger & Anderson Inc. acquired a new position in shares of Kenvue in the 1st quarter worth approximately $30,000. TruNorth Capital Management LLC acquired a new position in shares of Kenvue in the 1st quarter worth approximately $36,000. Truvestments Capital LLC acquired a new position in shares of Kenvue in the 1st quarter worth approximately $37,000. Clal Insurance Enterprises Holdings Ltd lifted its holdings in shares of Kenvue by 378.5% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company's stock worth $39,000 after acquiring an additional 1,287 shares during the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich lifted its holdings in shares of Kenvue by 120.6% in the 1st quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,699 shares of the company's stock worth $41,000 after acquiring an additional 929 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Trading Down 2.2%

NYSE KVUE opened at $15.88 on Thursday. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.68. The firm's fifty day moving average price is $19.99 and its 200 day moving average price is $21.68. The company has a market capitalization of $30.47 billion, a price-to-earnings ratio of 21.45, a price-to-earnings-growth ratio of 2.33 and a beta of 0.73. Kenvue Inc. has a 12 month low of $15.82 and a 12 month high of $25.17.

Kenvue (NYSE:KVUE - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $0.29 EPS for the quarter, beating analysts' consensus estimates of $0.28 by $0.01. The firm had revenue of $3.84 billion for the quarter, compared to the consensus estimate of $3.94 billion. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The company's revenue was down 4.0% on a year-over-year basis. During the same period last year, the firm posted $0.32 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, sell-side analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, August 27th. Investors of record on Wednesday, August 13th were given a $0.2075 dividend. This is a positive change from Kenvue's previous quarterly dividend of $0.21. The ex-dividend date of this dividend was Wednesday, August 13th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 5.2%. Kenvue's payout ratio is 112.16%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. Zacks Research upgraded shares of Kenvue to a "strong sell" rating in a report on Monday, August 11th. Royal Bank Of Canada reduced their target price on shares of Kenvue from $24.00 to $22.00 and set a "sector perform" rating on the stock in a report on Friday, August 8th. Evercore ISI reduced their target price on shares of Kenvue from $23.00 to $18.00 and set an "in-line" rating on the stock in a report on Tuesday, September 23rd. Citigroup reiterated a "neutral" rating on shares of Kenvue in a report on Tuesday, September 23rd. Finally, UBS Group reduced their target price on shares of Kenvue from $25.00 to $23.00 and set a "neutral" rating on the stock in a report on Thursday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $22.73.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.